Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2025—Diasorin has received FDA 510(k) clearance for the Simplexa COVID-19/Flu A/B and RSV Direct kit, a sample-to-answer test for the detection of SARS-CoV-2, influenza A and B virus, and respiratory syncytial virus directly from nasopharyngeal and nasal swab specimens. The kit runs on the Liaison MDX system and provides differential detection in about 45 minutes.
December 2025—The Journal of Clinical Microbiology has published an article describing ARUP Laboratories’ validation of a deep convolutional neural network to detect parasites in concentrated wet mounts of stool.
December 2025—Smart In Media has released version 3.2 of its PathoZoom Scan and LiveView. The new version includes enhancements to workflow, image transmission, and LIS integration.
December 2025—Qiagen has entered into a definitive agreement to fully acquire Parse Biosciences, a provider of scalable, instrument-free solutions for single-cell research, for $225 million. The acquisition will expand Qiagen’s Sample technologies portfolio into the single-cell sequencing market with highly scalable chemistry designed to power research involving millions of billions of cells, according to a press release from Qiagen. Parse’s scalable chemistry is also expected to accelerate growth in Qiagen’s digital insights bioinformatics business.
December 2025—The FDA has approved QuidelOrtho Corp.’s Micro Typing Systems DAT card, a gel-based solution for direct antiglobulin testing, and the Ortho Vision platform, an automated blood testing system.
December 2025—The Food and Drug Administration has granted expanded clearance for use of the FecalSwab sample type across all Qiagen QIAstat-Dx gastrointestinal panels, enabling full pathogen detection, including of Shiga toxin–producing E. coli and enteropathogenic E. coli. STEC and EPEC can now be reported when testing by FecalSwab collected from stool samples with the QIAstat-Dx Gastrointestinal Panel 2, including detection of clinically relevant STEC subtypes such as stx2f. STEC can now also be reported for the QIAstat-Dx GI Panel 2 Mini B and QIAstat-Dx GI Panel 2 Mini B&V.
December 2025—Proscia is introducing virtual staining, powered by Pictor Labs, to its Concentriq software platform to help laboratories reduce the costs associated with traditional chemical methods and drive efficiency in high-throughput workflows. Virtual staining uses AI models to replicate the effects of stains on tissue images. These models can generate a whole slide virtually stained image from label-free inputs in a few minutes. The company will integrate a menu of H&E, immunohistochemical, and special stains into Concentriq.
December 2025—GSI Group Holdings has acquired GenesisBPS, a designer and manufacturer of specialized benchtop blood processing equipment and laboratory consumables. GSI Group provides a wide range of laboratory single-use products, benchtop instruments, and related accessories and has locations across the U.S., Europe, and Asia. GenesisBPS joins GSI Group brands Globe Scientific, AmScope, Euromex, and Physix, among others.
November 2025—Streck added the Accellix automated cell phenotyping platform to its CD-Chex Plus (RUO) control.
November 2025—Bio-Rad Laboratories launched Specialty Immunoassay Plus in Europe, a comprehensive immunoassay quality control product for specialty immunoassay testing procedures.
